Genetic Technologies (NASDAQ:GENE) announces that initial sales of its GeneType for Breast Cancer Risk Assessment have now commenced in the U.S. via an online health platform, elicity by InTeleLabs, an independent telehealth medicine company.
The secure online health platform enables women meeting the required criteria to purchase the test and receive results via telehealth clinicians.
GeneType for Breast Cancer is a disease risk prediction test that provides results that inform individuals if they are at low, average or high-risk of developing breast cancer.
The test will sell for $249 and include the telemedicine consultations.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.